Atlas Trials

A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab

Clinical trial NCT04048577 · UNKNOWN

Trial details

NCT number
NCT04048577
Sponsor
Berkovich, Regina MD, PhD Inc.
Status
UNKNOWN
Phase
Phase 4
Study type
INTERVENTIONAL
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
Start date
2019-07-03
Primary completion
2021-11-01
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.